440O Afatinib (A) Vs Gefitinib (G) in Patients (pts) with EGFR Mutation-Positive (egfrm +) NSCLC: Overall Survival (OS) Sdata from LUX-Lung 7 (LL7)
K. Park,E.H. Tan,L. Zhang,V. Hirsh,K. O’Byrne,M. Boyer,J.C.-H. Yang,T. Mok,K.H. Lee,S. Lu,Y. Shi,S.-W. Kim,J. Laskin,D.-W. Kim,S.A. Laurie,K. Kölbeck,J. Fan,N. Dodd,A. Märten,L. Paz-Ares
DOI: https://doi.org/10.1016/s0923-7534(21)00598-6
IF: 51.769
2016-01-01
Annals of Oncology
Abstract:Background The irreversible ErbB family blocker, A, and the reversible EGFR TKI, G, are approved for 1st-line treatment (tx) of advanced EGFRmþ NSCLC. In the Phase IIb LL7 trial, A (40 mg/d) significantly improved PFS (HR 0.73 [95% CI 0.57–0.95], p=0.017), ORR (70 vs 56%, p=0.008) and time to tx failure (TTF; HR 0.73 [0.58–0.92], p=0.007) vs G (250 mg/d) in this setting. Here, we present primary analysis of OS. Methods LL7 assessed A vs G in tx- naı¨ve pts with stage IIIb/IV NSCLC and a common EGFR mutation (Del19/L858R). Co-primary endpoints were PFS, TTF and OS; other endpoints included ORR and AEs. Primary OS analysis was planned after_213 OS events and follow-up of≥32 mos. Results At data cut-off (8 Apr 2016), median follow-up for OS was 42.6 mos. Median tx duration was 13.7 (A) vs 11.5 (G) mos. 73%/77% (A/G) of pts who discontinued A/G had_1 subsequent systemic anticancer tx. 46%/56% (A/G) received a subsequent EGFR TKI; 20 (14%)/23 (15%) pts (A/G) received a 3rd-generation EGFR TKI. There was a trend towards improved OS with A vs G (median 27.9 vs 24.5 mos; HR 0.86 [0.66–1.12], p=0.258). Landmark 24-mo and 30-mo OS (A vs G) was 61% vs 51% and 8% vs 40%. Similar OS trends were seen with A vs G in pts with Del19 (30.7 vs 26.4 mos; HR 0.83 [0.58–1.17]) and L858R (25.0 vs 21.2 mos; HR 0.92 [0.62–1.36]) mutations. There was a trend towards improved OS with A vs G in pts who received a 3rd-generation EGFR TKI (NE vs 46.0 mos; HR 0.51 [0.17–1.52]). Consistent OS outcomes were observed across age groups in the A arm (median, mos: 27.9 [≥60 yrs]; 26.7 [≥65 yrs]; 25.1 [≥70 yrs]; 27.9 [≥75 yrs]). 74/62 (46%/39%; A/G) pts survived for >30 mos; of patients who received A,>30-mo survival rates were generally similar across countries of origin and mean average dose received. Similar to the primary analyses, updated PFS, TTF and ORR data were significantly improved with A vs G. The AE profile of A and G was virtually unchanged since the primary analysis. Conclusions In LL7, there was a trend towards improved OS with A vs G that was generally consistent across subgroups. Updated PFS (independent review), TTF and ORR all significantly favored A over G. Clinical trial indentification ClinTrials.gov:NCT01466660/EudraCT:2011-001814-33 (release date: 2011-12-29) Legal entity responsible for the study N/A Funding Boehringer Ingelheim Disclosure K. Park: Advisory board: BI; Corporate-sponsored research: AZ. L. Zhang: Advisory board: AstraZeneca, BMS; Corporate-sponsored research: BMS, Pfizer, Lilly; Honoraria: AZ, Roche, Lilly. V. Hirsh: Advisory board: AstraZeneca, Roche, Pfizer, Merck, Boehringer Ingelheim, Amgen, Lilly; Honoraria: AstraZeneca, Roche, Pfizer, Merck, Boehringer Ingelheim, Amgen, Lilly. K. O'Byrne: Honoraria: Pfizer, Roche, AZD, BI, BMS, MSD, Lilly Oncology, Novartis; Consultancy/Advisory: Pfizer, Roche, AZD, Lilly Oncology, MSD, BI; Travel expenses: Roche, AZD, BI, MSD; Stock: CARP Pharmaceuticals; TCD Ref L002-310-01, US patent 13/601,703 entitled “Global Analysis of Serum mircoRNAs as Potential Biomarkers for Lung Adenocarcinoma [filed 31.08.12); Australian Provisional Patent Number 2015905380 entitled “Nucleic Acid Oligomers and Uses the rof. M. Boyer: Advisory board: Merck, Bristol Myers, Pfizer Corporate-sponsored research: Merck, Bristol Myers, Boehringer Ingelheim, Amgen, Clovis, Astra Zeneca, Eli Lilly, Novartis. J.C-H. Yang: Advisory board (and honoraria TBC): Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astrazeneca, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Innopharma, Merrimack. T. Mok: Stock ownership: Sanomics Ltd; Advisory board: AZ, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Inc., Vertex Pharmaceuticals, Aveo & Biodesix, BMS, geneDecode Co., Ltd., Onco Genex Technologies Inc.; Board of directors: IASLC, Chinese Lung Cancer Research Foundation Ltd., Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Therapy Society (HKCTS); Corporate-sponsored research: AZ, BI, Pfizer, Novartis, SFJ, Roche, MSD, Clovis Oncology, BMS. J. Fan, N. Dodd, A. Märten: Employment: Boehringer Ingelheim. L. Paz-Ares: Honoraria: Pfizer, Boehringer Ing, Lilly, Roche, BMS, MSD, Novartis, Amgen. All other authors have declared no conflicts of interest.